Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1526-1536

  Wu, Xuping ^a,e   Sooman, Linda ^a   Wickstrom, Malin ^b   Fryknas, Marten ^b   Dyrager, Christine ^d   Lennartsson, Johan ^c   Gullbo, Joachim ^b  

^a Section of Oncology   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE 3; PICROPODOPHYLLIN; PODOPHYLLIN; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CHIRALITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; MICROTUBULES; PHOSPHORYLATION; PODOPHYLLOTOXIN; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUBULIN MODULATORS;

EID: 84882238346     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0091     Document Type: Article

References (41)

1. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7.
2. Maki RG. Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-95.
3. Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
4. Yu WW, Guo YM, Zhu M, Cai XW, Zhu ZF, Zhao WX, et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: A meta-analysis. Hepatogastroenterology 2011;58:426-31.
5. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012;18:40-50.
6. Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials 2010;5:189-208.
7. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107:655-60.
8. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42.
9. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004;23:7854-62.
10. Ekman S, Frodin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, et al. Clinical phase I study with an Insulin-like growth factor-1 receptor inhibitor: Experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011;50:441-7.
11. Ekman S, Harmenberg J, Hedlund AJ, Bergstrom S, Frodin JE, Bergqvist M. A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma [Abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011; Orlando, FL: Orange County Convention Center. Philadelphia (PA): AACR.
12. Ekman S, Harmenberg J, Stahl B, Hedlund A, Bergstrom S, Frodin J, et al. Phase I dose-escalation study of AXL1717-A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung carcinoma. [Abstract]. In: Proceedings of the 2011 European Multidisciplinary Cancer Congress; 2011; Stockholm, Sweden: European Journal of Cancer.
13. Cortese F, Bhattacharyya B, Wolff J. Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem 1977;252:1134-40.
14. Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res 1978;38:2688-93.
15. Gensler WJ, Gatsonis CD. The podophyllotoxin-picropodophyllin equilibrium. J Org Chem 1966;31:3224-7.
16. Linder S, Shoshan MC, Gupta RS. Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor. Cancer Res 2007;67:2899.
17. Lennartsson J, Wardega P, Engstrom U, Hellman U, Heldin C-H. Alix facilitates the interaction between c-Cbl and platelet-derived growth factor beta-receptor and thereby modulates receptor down-regulation. J Biol Chem 2006;281:39152-8.
18. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008;3:1364-9.
19. Maestro 9.0 unified interface for Schrödinger software 2009. Available from http://www.schrodinger.com/productpage/14/12/.
20. Glide 2.1 ligand-receptor docking 2009, Available from http://www. schrodinger.com/productpage/14/5/.
21. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.
22. Bonne D, Heusele C, Simon C, Pantaloni D. 40,6-Diamidino-2-phenylindole, a fluorescent-probe for tubulin and microtubules. J Biol Chem 1985;260:2819-25.
23. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W, Larsson R. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 2000;36: 2120-7.
24. Kim DY, Kim KH, Kim ND, Lee KY, Han CK, Yoon JH, et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem 2006;49:5664-70.
25. Gupta S, Das L, Datta AB, Poddar A, Janik ME, Bhattacharyya B. Oxalone and lactone moieties of podophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin. Biochemistry 2006;45:6467-75.
26. Wu X, Sooman L, Lennartsson J, Bergstrom S, Bergqvist M, Gullbo J, et al. Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells. Int J Oncol 2013; 42:297-304.
27. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 2009;9: 748-60.
28. Sohda M, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, et al. The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer. Anticancer Res 2004;24:3029-34.
29. Yilmaz O, Eroglu A, Dag E, Karaoglanoglu N, Yilmaz A. Serum levels of IGF-I and IGFBP-III and their relation with carcinoembryonic antigen and carbohydrate antigen 19-9 in cases of esophageal cancer. Int J Clin Pract 2006;60:1604-8.
30. Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, et al. Insulinlike growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 2007;28:947-56.
31. Tchorzewski MT, Qureshi FG, Duncan MD, Duncan KL, Saini N, Harmon JW. Role of insulin-like growth factor-I in esophageal mucosal healing processes. J Lab Clin Med 1998;132:134-41.
32. Liu YC, Leu CM, Wong FH, Fong WS, Chen SC, Chang C, et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002;9:665-74.
33. Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008;27:1629-38.
34. Feng X, Aleem E, Lin Y, Axelson M, Larsson O, Stromberg T. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications. Int J Oncol 2012;40:1251-8.
35. Doghman M, Axelson M, Lalli E. Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation. Am J Cancer Res 2011;1:356-61.
36. Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 2004;279:1713-9.
37. Rodland KD, Bollinger N, Ippolito D, Opresko LK, Coffey RJ, Zangar R, et al. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008;283:31477-87.
38. Rosengren L, Vasilcanu D, Vasilcanu R, Fickenscher S, Sehat B, Natalishvili N, et al. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun 2006;347:1059-66.
39. Ronquist-Nii Y, Eksborg S, Axelson M, Harmenberg J, Beck O. Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879: 326-34.
40. Hashemi J, Worrall C, Vasilcanu D, Fryknas M, Sulaiman L, Karimi M, et al. Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS ONE 2011;6:e14757.
41. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009;15:6454-61.